AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
The Source
CNBC
US
IRS chief Frank Bisignano laughs off JPMorgan spying allegations
CNBC·1h ago·3 min read
US
Nvidia details its next-generation Vera CPU for AI, setting up challenge to AMD and Intel
CNBC·2h ago·3 min read
US
SpaceX sets earnings date, triggering first lock-up expiration for millions of shares
CNBC·3h ago·3 min read
Health
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
CNBC·3h ago·3 min read
Related
On this beat
Health
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
CNBC·3h ago·3 min read
Health
1,700 H.I.V. Treatment Sites Closed After Trump Aid Cuts, a Study Finds
TNYT·3h ago·3 min read
Health
Smash Chicken Caesar Tacos
WELNESS MAMA·4h ago·3 min read
Health
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
TWSJ·5h ago·3 min read